AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) Files An 8-K Submission of Matters to a Vote of Security Holders

AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07

Submission of Matters to a Vote of Security
Holders.

Ampio Pharmaceuticals, Inc. (the Company) held its Annual Meeting
of Stockholders on January7, 2017. The number of shares of common
stock entitled to vote at the annual meeting was 57,179,686. The
number of shares of common stock present, in person or
represented by proxy, and entitled to vote at the annual meeting
was 40,310,393. All matters submitted to a vote of our
stockholders at the annual meeting were approved and all director
nominees were elected.

The certified results of each of the matters voted upon at the
annual meeting, which are more fully described in our definitive
proxy statement, are as follows:

(1) Election of five (5)directors for terms expiring at the 2017
annual meeting of stockholders.


DIRECTORS


FOR

WITHHELD


MichaelMacaluso

10,829,626 1,995,560


DavidBar-Or,M.D.

10,777,922 2,047,264


Philip H. Coelho

11,090,701 1,734,485


Richard B. Giles

11,272,531 1,552,655


DavidR.Stevens,Ph.D.

11,279,586 1,545,600


There were 27,485,207 broker non-votes regarding this
proposal.

(2) Ratification of the selection of EKSH LLLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2016.


FOR


AGAINST

ABSTAIN


39,445,732

275,533 589,128


There were no broker non-votes regarding this proposal.


About AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE)

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) Recent Trading Information

AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) closed its last trading session up +0.017 at 0.997 with 248,126 shares trading hands.

An ad to help with our costs